Online citations, reference lists, and bibliographies.

Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, And Other Antacid Medications And The Risk Of Fracture

P. Vestergaard, L. Rejnmark, L. Mosekilde
Published 2006 · Medicine, Biology
Cite This
Download PDF
Analyze on Scholarcy
We studied the effect of proton pump inhibitors, histamine H2 receptor antagonists, and other types of antacid drugs on fracture risk. All cases were subjects with any fracture sustained during the year 2000 (n = 124,655). For each case, three controls (n = 373,962) matched on age and gender were randomly drawn from the background population. The primary exposure variables were use of proton pump inhibitors, histamine H2 antagonists, and other antacid drugs. Adjustments were made for several confounders, including diagnosis of an ulcer, nonsteroidal anti-inflammatory drug use, use of histamine H1 antagonists, stomach resection, previous fracture, and use of corticosteroids. The effect of dose was examined by stratifying for cumulated dose (defined daily dose). Use of proton pump inhibitors was associated with an increase in fracture risk for use within the last year [odds ratio (OR) = 1.18, 95% confidence interval (CI) 1.12–1.43 for overall fracture risk; OR = 1.45, 95% CI 1.28–1.65 for hip fractures; and OR = 1.60, 95% CI 1.25–2.04 for spine fractures). Histamine H2 antagonists were associated with a decreased fracture risk if they had been used within the last year (OR = 0.88, 95% CI 0.82–0.95 for any fracture, OR = 0.69, 95% CI 0.57–0.84 for hip fractures). Other antacids were not associated with overall fracture risk but were associated with hip and spine fractures. Proton pump inhibitors appeared to be associated with a limited increase in fracture risk, in contrast to histamine H2 antagonists, which seemed to be associated with a small decrease in fracture risk. In all cases, the changes in risk estimates were small and the clinical significance was limited.
This paper references
5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
Stefania Gagliardi (1998)
H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model.
C. Dobigny (1997)
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Tem Frank Andersen (1999)
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism
P. Vestergaard (2000)
Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
Jiake Xu (2003)
Bone Mineral Density in Patients Taking H2-Receptor Antagonist
Y. Adachi (1998)
Effects of a proton-pump inhibitor in cystic fibrosis.
T M Tran (1998)
Fracture risk associated with use of antiepileptic drugs.
Peter Vestergaard (2004)
Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark.
Peter Vestergaard (2002)
Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study.
Peter Vestergaard (2002)
The Pharmacoepidemiologic Prescription Database of North Jutland - a valid tool in pharmacoepidemiological research.
G. Nielsen (1997)
Recent advances in the ultrastructural assessment of osteoclastic resorptive functions.
Takahisa Sasaki (1996)
The Danish Psychiatric Central Register.
P. Munk-jørgensen (1997)
Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies.
S. Høidrup (1999)
Risk factors for hip fracture in men. Hip Fracture Study Group.
J. Grisso (1997)
Proton Pump Inhibitors Control Osteoclastic Resorption of Calcium Phosphate Implants and Stimulate Increased Local Reparative Bone Growth
Kathy Rzeszutek (2003)
Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorption.
K. Sundquist (1990)
The Danish National Patient Register: evaluation of data quality [in Danish
J Mosbech (1995)
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
Histamine participates in the early phase of trabecular bone loss in ovariectomized rats.
P. Lesclous (2004)
The histamine H2-receptor antagonist, cimetidine, inhibits the articular osteopenia in rats with adjuvant-induced arthritis by suppressing the osteoclast differentiation induced by histamine.
Katsunori Yamaura (2003)
Gastrectomy causes bone loss in the rat: is lack of gastric acid responsible?
Petra Persson (1993)
Mechanisms of proton transport in isolated rat osteoclasts attached to bone.
Toshiyuki Shibata (2000)
Selective inhibition of osteoclast vacuolar H(+)-ATPase.
C. Farina (2002)
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.
C M Klotzbuecher (2000)
Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
J. P. Mattsson (1991)
A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
L. Visentin (2000)
Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Takako Sahara (2003)
Alcohol intake as a risk factor for fracture
John A. Kanis (2004)
Fracture risk associated with systemic and topical corticosteroids.
Peter Vestergaard (2005)
Short-term prevention of osteoclastic resorption and osteopenia in ovariectomized rats treated with the H(2) receptor antagonist cimetidine.
P. Lesclous (2002)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M. Charlson (1987)
Selection of Controls in Case-Control Studies
Shdom WachokJer (2004)

This paper is referenced by
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
R. Kuan (2013)
Risk Factors for Falls with Use of Acid-Suppressive Drugs
Lucía Cea-Soriano (2013)
Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation
Devyani Misra (2014)
Osteoporosis in men
Gretchen M. Dickson (2011)
Proton pump inhibitors: balancing the benefits and potential fracture risks
J. Brent Richards (2008)
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
Nicholas R Latimer (2009)
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
Elaine W Yu (2008)
Nutrición y osteoporosis. Calcio y vitamina D
Quesada Gómez Jm (2011)
Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications
Joel J. Heidelbaugh (2013)
Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso
Gabriela Rezende Yanagihara (2015)
Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women
Julie M Paik (2018)
Développement d’un système automatisé de détection et de priorisation des signaux de sécurité adapté aux bases de données médico-administratives
Mickael Arnaud (2017)
Proton pump inhibitors and osteoporosis
Bjarne Nesgaard Andersen (2016)
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.
Joel J. Heidelbaugh (2010)
The Incidence of Hip Fracture Associated with Proton Pump Inhibitor (PPI) and/or H2 Receptor Antagonist (H2RA) Use in the Kentucky Medicaid Population
Timothy C. Umeh (2011)
Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies
S. Ngamruengphong (2011)
O czym warto pamiętać, stosując przewlekle inhibitory pompy protonowej?
Tomasz Wocial (2013)
pump inhibitors : adverse effects beyond ( over ) utilization ?
Paolo Montanari (2010)
PPI Long Term Use: Risk of Neurological Adverse Events?
Michal Novotny (2019)
Gastroprotection in the treatment of erosive and ulcerative lesions of the stomach and small intestine
E. Yu. Plotnikova (2020)
The impact of proton pump inhibitors on bone regeneration and implant osseointegration
Alexandru Mester (2019)
Nutritional consequences of long-term acid suppression; are they clinically important?
David Alan Johnson (2016)
Clinical Considerations for Proton Pump Inhibitor (PPI) Use
Gregory W. H. Smith (2010)
Update on Medications With Adverse Skeletal Effects CONCISE REVIEW FOR CLINICIANS
C. J. Pitts (2011)
Short-term safety and symptomatic outcomes of transoral incisionless fundoplication with or without hiatal hernia repair in patients with chronic gastroesophageal reflux disease.
Glenn Michael Ihde (2011)
Hypersensitivity Reactions to Proton Pump Inhibitors
Carla Lombardo (2015)
Are proton pump inhibitors really so dangerous?
Vincenzo Savarino (2016)
What you need to know when you prescribe a proton pump inhibitor
Al Norman (2011)
Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy
Mathias B. Krause (2014)
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
K. Aasarød (2016)
An updated meta-analysis : the effect of proton pump inhibitor on risk of osteoporosis and fracture
Xiu-De Fan (2017)
Proton pump inhibitors – are they truly safe?
Agnieszka Jankowska (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar